HOVON-SAKK132试验中CD34+CD38-急性髓系白血病干细胞频率预后相关性的前瞻性验证 - Suppr

Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.

作者信息

Ngai Lok Lam, Hanekamp Diana, Janssen Fleur, Carbaat-Ham Jannemieke, Hofland Maaike A M A, Fayed Mona M H E, Kelder Angèle, Oudshoorn-van Marsbergen Laura, Scholten Willemijn J, Snel Alexander N, Bachas Costa, Tettero Jesse M, Breems Dimitri A, Fischer Thomas, Gjertsen Bjørn T, Griškevičius Laimonas, Juliusson Gunnar, van de Loosdrecht Arjan A, Maertens Johan A, Manz Markus G, Pabst Thomas, Passweg Jakob R, Porkka Kimmo, Valk Peter J M, Gradowska Patrycja, Löwenberg Bob, de Leeuw David C, Janssen Jeroen J W M, Ossenkoppele Gert J, Cloos Jacqueline

机构信息

Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Cancer Cancer Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.

出版信息

Blood. 2023 May 25;141(21):2657-2661. doi: 10.1182/blood.2022019160.

DOI:10.1182/blood.2022019160

PMID:36898087

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10646801/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21d5/10646801/cb20db6161f1/BLOOD_BLD-2022-019160-fx1.jpg

相似文献

Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.HOVON-SAKK132试验中CD34+CD38-急性髓系白血病干细胞频率预后相关性的前瞻性验证

Blood. 2023 May 25;141(21):2657-2661. doi: 10.1182/blood.2022019160.

[Characteristic and prognostic significance of leukemia stem cells associated antigens expressions in t (8;21) acute myeloid leukemia].[伴t(8;21)急性髓系白血病中白血病干细胞相关抗原表达的特征及预后意义]

Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):831-836. doi: 10.3760/cma.j.issn.0253-2727.2019.10.007.

High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.儿童急性髓系白血病诊断时白血病干细胞比例高与不良预后相关。

Pediatr Hematol Oncol. 2011 Mar;28(2):91-9. doi: 10.3109/08880018.2010.528171. Epub 2011 Jan 8.

CD45CD34CD38CD133 cells have the potential as leukemic stem cells in acute myeloid leukemia.CD45CD34CD38CD133 细胞在急性髓细胞白血病中具有白血病干细胞的潜能。

BMC Cancer. 2020 Apr 6;20(1):285. doi: 10.1186/s12885-020-06760-1.

Leukemic Stem Cell (CD34/CD38/TIM3) Frequency in Patients with Acute Myeloid Leukemia: Clinical Implications.急性髓系白血病患者白血病干细胞（CD34/CD38/TIM3）频率：临床意义。

Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):508-513. doi: 10.1016/j.clml.2021.03.009. Epub 2021 Mar 27.

CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.通过多参数流式细胞术检测的CD34 + CD38-CLL1+白血病干细胞持续性是成年急性髓系白血病患者预后不良的生物标志物。

Leuk Lymphoma. 2022 Apr;63(4):996-1000. doi: 10.1080/10428194.2021.2005042. Epub 2021 Nov 21.

[In Vitro Identification and Characteristics of CD34 Leukemia Stem Cell in t(8;21) Acute Myeloid Leukemia].[8;21) 急性髓系白血病中CD34白血病干细胞的体外鉴定及特性]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1289-1294. doi: 10.7534/j.issn.1009-2137.2017.05.003.

Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.通过多参数流式细胞术检测到的白细胞单采产物中CD34 + CD38-细胞的较高百分比预示着急性髓系白血病的完全缓解不能持续。

Leuk Lymphoma. 2015 Mar;56(3):622-9. doi: 10.3109/10428194.2014.927453. Epub 2014 Jul 17.

Live kinase B1 maintains CD34CD38 AML cell proliferation and self-renewal.活激酶 B1 维持 CD34CD38 AML 细胞的增殖和自我更新。

Mol Cell Biochem. 2017 Oct;434(1-2):25-32. doi: 10.1007/s11010-017-3032-y. Epub 2017 Apr 10.

Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.CD34/CD38 与侧群（SP）在急性髓系白血病中的白血病干细胞区室的关系。

Leuk Res. 2019 Jun;81:27-34. doi: 10.1016/j.leukres.2019.04.004. Epub 2019 Apr 9.

引用本文的文献

Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.用于预测接受同种异体移植的急性髓系白血病患者复发的白血病干细胞：一项前瞻性研究的长期随访

Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02699-8.

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.CD34+CD38-白血病干细胞可预测接受低甲基化药物非强化治疗的急性髓系白血病患者的临床结局。

Leukemia. 2025 Apr;39(4):972-975. doi: 10.1038/s41375-025-02539-0. Epub 2025 Feb 27.

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.可测量残留病在接受异基因造血细胞移植治疗急性髓系白血病患者中的意义

Cells. 2025 Feb 15;14(4):290. doi: 10.3390/cells14040290.

Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.对处于完全缓解（CR）状态并接受异基因干细胞移植的急性髓系白血病（AML）患者中具有白血病干细胞（LSC）相关表型的细胞进行移植后流式微小残留病（flow-MRD）评估。

Leukemia. 2024 Feb;38(2):386-388. doi: 10.1038/s41375-024-02148-3. Epub 2024 Jan 23.

Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.了解 MRD 检测的差异化技术以及如何将其纳入临床实践。

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):682-690. doi: 10.1182/hematology.2023000454.

Perspective on measurable residual disease testing in acute myeloid leukemia.急性髓系白血病中可测量残留病检测的前景

Leukemia. 2024 Jan;38(1):10-13. doi: 10.1038/s41375-023-02084-8. Epub 2023 Nov 16.

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.酪蛋白激酶2（CK2）：急性髓系白血病中一个可能的治疗靶点。

Cancers (Basel). 2023 Jul 21;15(14):3711. doi: 10.3390/cancers15143711.

本文引用的文献

Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.急性髓系白血病中大量及白血病干细胞可测量残留病的无监督早期评估的预后影响

Clin Cancer Res. 2023 Jan 4;29(1):134-142. doi: 10.1158/1078-0432.CCR-22-2237.

Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.急性髓系白血病移植后维持治疗的新机制

Front Oncol. 2022 Jul 12;12:892289. doi: 10.3389/fonc.2022.892289. eCollection 2022.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议

Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.

An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study.一项基于LSC的MRD检测，以补充传统MFC方法预测AML复发：一项前瞻性研究。

Blood. 2022 Aug 4;140(5):516-520. doi: 10.1182/blood.2021014604.

Leuk Lymphoma. 2022 Apr;63(4):996-1000. doi: 10.1080/10428194.2021.2005042. Epub 2021 Nov 21.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.2021 年急性髓系白血病微小残留病更新：来自欧洲白血病网微小残留病工作组的共识文件。

Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626.

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.在新诊断为 AML 的年轻和中年成年人中强化治疗中添加来那度胺：HOVON-SAKK-132 试验。

Blood Adv. 2021 Feb 23;5(4):1110-1121. doi: 10.1182/bloodadvances.2020003855.

CD34CD38CD123 Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.CD34CD38CD123白血病干细胞频率可预测接受强化化疗而非去甲基化药物治疗的老年急性髓系白血病患者的预后。

Cancers (Basel). 2020 May 6;12(5):1174. doi: 10.3390/cancers12051174.

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.多中心环境下急性髓系白血病干细胞评估的适用性和可重复性。

Br J Haematol. 2020 Sep;190(6):891-900. doi: 10.1111/bjh.16594. Epub 2020 Apr 2.

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.验证和完善 2017 年修订的欧洲白血病网络急性髓系白血病遗传风险分层。

Leukemia. 2020 Dec;34(12):3161-3172. doi: 10.1038/s41375-020-0806-0. Epub 2020 Mar 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献